Internet marketing of neuroproducts: new practices and healthcare policy challenges.
Internet marketing of neuroproducts: new practices and healthcare policy challenges.
复制标题
神经产品的网络营销：新实践和医疗保健政策挑战。
DOI：
10.1017/s096318010707020x
复制
发表时间：
2007
期刊：
影响因子：
--
通讯作者：
Illes,Judy
中科院分区：
文献类型：
--
作者：
Racine,Eric;vanderLoos,HZAdriaan;Illes,Judy
直接面向消费者的保健产品广告是指通过不同媒体，如电台和电视广播、报纸和杂志广告，以及最近通过互联网，以针对消费者的信息和促销策略为基础的各种营销做法。制药业使用的主要营销形式是向医生分发免费样品，但DTCA在全球处方药促销支出中所占比例越来越大。最新的估计表明，DTCA现在是美国制药业每年32亿美元的企业。从文献中的结果表明，这些实质性的努力是面向具有巨大市场潜力的慢性疾病的新药物。最大的份额将流向20种最常用的药物。我们感谢亨利J.凯泽家庭基金会（J. I.）感谢Patricia King博士对该项目的支持。本文的撰写得到了NIH/NINDS R 01 #NS045831（J.I.）和加拿大社会科学和人文科学研究理事会（E.R.）。我们还感谢Pamela Schraedley-Desmond博士，Shilpa Gulati，Neil Mukhopadhyay和Sarah Waldman。
Direct-to-consumer advertising (DTCA) of healthcare products refers to a variety of marketing practices based on a combination of information and promotion strategies directed at consumers through different media such as radio and television broadcasts, newspaper and magazine ads, and, more recently, through the Internet. The principal form of marketing used by the pharmaceutical industry is the distribution of free samples to physicians but DTCA is an increasing part of global promotional spending for prescription drugs. Latest estimates suggest that DTCA now represents an annual $3.2 billion enterprise for the U.S. pharmaceutical industry. Findings from the literature show that these substantial efforts are geared toward the newer pharmaceuticals for chronic conditions with huge market potentials. The lion's share is going to the 20 most prescribed pharmaceuticals.We thank the Henry J. Kaiser Family Foundation (J.I.) for funding of this project and Dr. Patricia King for her support. Writing of this paper was supported by NIH/NINDS R01 #NS045831 (J.I.) and the Social Sciences and Humanities Research Council of Canada (E.R.). We also acknowledge Dr. Pamela Schraedley-Desmond, Shilpa Gulati, Neil Mukhopadhyay, and Sarah Waldman.